Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy — Stella

Home/Triple Negative Breast Cancer (TNBC)/

View on ClinicalTrials.gov

Recruiting

Back to Triple Negative Breast Cancer (TNBC) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Portugal

Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Região

Key details

Phase

Early testing / Safety & dosing

Sponsor

Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

Enrollment target

~20 participants

Started

September 2024

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Sex

Female only

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.